Initital data from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits.

Survey to assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists.

Assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients

Expert panel of 8 dermatologists from the Skin Cancer Prevention Working Group developed 6 concensus statements supporting the appropriate use of GEP testing

Independent mulit-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.

Meta-analysis stage I-II patients. GEP consistently identifies melanoma patients at increased risk of metastasis, independent of clinicopathologic features and can be used in conjunction with traditional staging to improve patient risk stratification.

Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition

Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes

GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients

The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.

he incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) in the Medicare population are rapidly increasing. The current national guidelines are broad and the available staging systems for stratification are inadequate to accurately guide patient management.

A method for objective quantification of epithelial and stromal biomarkers to generate a tissue profile aiding predictive models for cancer pathology.